Annual Reports in Medicinal Chemistry

• Personal Essay Reflections on Medicinal Chemistry at Merck, West PointPaul S. AndersonMy Path in Seeking New MedicinesPeter R. BernsteinTales of Drug Discovery M. Ross JohnsonI. Central Nervous System DiseasesSection Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, MassachusettsRecent Developments in Targeting Neuroinflammation in DiseaseAllen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. StaalSecretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer’s DiseaseHarrie J. M. Gijsen and François P. BischoffmGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS DisordersSylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe RocherNMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes – Recent Results and Developments Kamalesh B. Ruppa, Dalton King and Richard OlsonRecent Advances in the Development of PET and SPECT Tracers for Brain ImagingLei Zhang and Anabella VillalobosII. Cardiovascular and Metabolic DiseasesSection Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New JerseyCase History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic DiseasesDonald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler AMPK Activation in Health and DiseaseIyassu K. Sebhat and Robert W. MyersType-2 Diabetes and Associated Co-Morbidities as an Inflammatory SyndromeJuan C. Jaen, Jay P. Powers and Tim SullivanBeyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 DiabetesPhilip A. Carpino and David HepworthIII. Inflammatory Pulmonary and Gastrointestinal DiseasesSection Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New JerseyRecent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor AgonistsAlaric J. DyckmanBifunctional Compounds for the Treatment of COPD Gary Phillips and Michael SalmonInflammatory Targets for the Treatment of Atherosclerosis Robert O. Hughes, Alessandra Bartolozzi and Hidenori TakahashiIV. OncologySection Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, AustraliaNanotechnology Therapeutics in Oncology – Recent Developments and Future OutlookPaul F. RichardsonSmall-Molecule Antagonists of Bcl-2 Family ProteinsSean P. Brown and Joshua P. TaygerlyNotch Pathway Modulators as Anti-Cancer ChemotherapeuticsVibhavari Sail and M. Kyle HaddenAnaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo TsukudaV. Infectious DiseasesSection Editor: John Primeau, Westford, MassachusettsRecent Advances in the Discovery of Dengue Virus InhibitorsJeremy Green, Upul Bandarage, Kate Luisi and Rene RijnbrandNon Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TBPravin S. Shirude and Shahul HameedHCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replication Complex Robert Hamatake, Andrew Maynard and Wieslaw M. KazmierskiVI. Topics in BiologySection Editor: John Lowe, JL3Pharma LLC, Stonington, ConnecticutAntibody-Drug Conjugates for Targeted Cancer TherapyVictor S. Goldmacher, Thomas Chittenden, Ravi V. J. Chari, Yelena V. Kovtun and John M. Lambert3D Cell Cultures: Mimicking in Vivo Tissues for Improved Predictability in Drug DiscoveryIndira Padmalayam and Mark J. SutoVirally Encoded G Protein-Coupled Receptors: Overlooked Therapeutic Opportunities?Nuska TschammerRecent Advances in Wnt/b-Catenin Pathway Small Molecule InhibitorsDaniel D. Holsworth and Stefan KraussVII. Topics in Drug Design and DiscoverySection Editor: Peter R. Bernstein, PhaRmaB LLC, Rose Valley, PennsylvaniaTargeted Covalent Enzyme InhibitorsMark C. Noe and Adam M. GilbertDrug Design Strategies for GPCR Allosteric ModulatorsP. Jeffrey Conn, Scott D. Kuduk and Darío DollerProgress in the Development of Non-ATP Competitive Protein Kinase Inhibitors for OncologyCampbell McInnesVIII. TrendsSection Editor: Joanne Bronson, Bristol-Myers Squibb, Wallingford, ConnecticutNew Chemical Entities Entering Phase III Trials in 2011Gregory T. NotteTo Market, To Market – 2011Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg

This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." --Enzymologia